Abstract:Although dyslipidemia commonly occurs in patients with acute promyelocytic leukemia (APL) in response to anti-APL therapy, the underlying mechanism and the lipid statuses of patients with newly diagnosed APL remain to be addressed. Methods: We conducted a retrospective study to investigate the lipid profiles of APL patients. PML-RARα transgenic mice and APL cells-transplanted mice were used to assess the effects of APL cells on the blood/liver lipid levels. Subsequently, gene set enrichment analysis, western blot and dual luciferase reporter assay were performed to examine the role and mechanism of PML-RARα and TRIB3 in lipid metabolism regulation in APL patients at pretreatment and after induction therapy. Results: APL patients exhibited a higher prevalence of dyslipidemia before anti-APL therapy based on a retrospective study. Furthermore, APL cells caused secretion of triglycerides, cholesterol, and PCSK9 from hepatocytes and degradation of low-density lipoprotein receptors in hepatocytes, which elevated the lipid levels in APL cell-transplanted mice and Pml-Rarα transgenic mice. Mechanistically, pseudokinase TRIB3 interacted with PML-RARα to inhibit PPARγ activity by interfering with the interaction of PPARγ and RXR and promoting PPARγ degradation. Thus, reduced PPARγ activity in APL cells decreased leptin but increased resistin expression, causing lipid metabolism disorder in hepatocytes and subsequent dyslipidemia in mice. Although arsenic/ATRA therapy degraded PML-RARα and restored PPARγ expression, it exacerbated dyslipidemia in APL patients. The elevated TRIB3 expression in response to arsenic/ATRA therapy suppressed PPARγ activity by disrupting the PPARγ/RXR dimer, which resulted in dyslipidemia in APL patients undergoing therapy. Indeed, the PPAR activator not only enhanced the anti-APL effects of arsenic/ATRA by suppressing TRIB3 expression but also reduced therapy-induced dyslipidemia in APL patients. Conclusion: Our work reveals the critical role of the PML-RARα/PPARγ/TRIB3 axis in the development of dyslipidemia in APL patients, potentially conferring a rationale for combining ATRA/arsenic with the PPAR activator for APL treatment.

Targeting Pseudokinase TRIB3 Brings about a New Therapeutic Option for Acute Promyelocytic Leukemia

RBCK1‐TRIB3 decelerated the progression of acute promyelocytic leukemia

Data from TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

TRIB3 Inhibits Proliferation and Promotes Osteogenesis in Hbmscs by Regulating the ERK1/2 Signaling Pathway.

Diverse functions of TRIB3 in cancers and its potential as a therapeutic target

Trib3 Promotes The Proliferation And Invasion Of Renal Cell Carcinoma Cells Via Activating Mapk Signaling Pathway

Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target.

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target

TRIB3 promotes malignancy of head and neck squamous cell carcinoma via inhibiting ferroptosis

Current Progress in Delineating the Roles of Pseudokinase TRIB1 in Controlling Human Diseases

Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy

Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia Through Ubiquitination and Degradation of PML-RARα

PML-RARα Interaction with TRIB3 Impedes PPARγ/RXR Function and Triggers Dyslipidemia in Acute Promyelocytic Leukemia.

TRIB3‒GSK-3β interaction promotes lung fibrosis and serves as a potential therapeutic target

In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia

Oncogenic Roles of Prl-3 in Flt3-Itd Induced Acute Myeloid Leukaemia

Palmitoyltransferase ZDHHC3 is essential for the oncogenic activity of PML/RARα in acute promyelocytic leukemia

RNA-binding Proteins As Drivers of AML and Novel Therapeutic Targets.

Targeting PRL phosphatases in hematological malignancies

Rapid increase of C/EBPα p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1 -expressing AML